Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 752.84 million, representing an increase of 28.50% compared to RMB 585.88 million in 2022[2]. - Gross profit for the same period was RMB 438.07 million, up 31.76% from RMB 332.49 million in the previous year[2]. - Net profit for the year was RMB 153.23 million, reflecting a growth of 14.50% from RMB 133.83 million in 2022[3]. - Basic and diluted earnings per share were both RMB 0.92, compared to RMB 0.79 and RMB 0.78 respectively in the prior year, marking increases of 16.46% and 17.95%[3]. - Total comprehensive income for the year was RMB 153.69 million, compared to RMB 135.72 million in 2022, indicating an increase of 13.23%[6]. Assets and Liabilities - Non-current assets increased to RMB 1,305.34 million as of December 31, 2023, from RMB 1,025.39 million in 2022, showing a growth of 27.38%[7]. - Current liabilities decreased to RMB 724.29 million in 2023 from RMB 801.94 million in 2022, a reduction of 9.66%[8]. - The company's total equity increased to RMB 1,678.38 million in 2023, up from RMB 1,554.10 million in the previous year, representing an increase of 8.00%[9]. - The company reported a significant increase in trade and other receivables, which rose to RMB 125.19 million in 2023 from RMB 79.53 million in 2022, an increase of 57.38%[7]. Revenue Breakdown - Revenue from cardiovascular and neurovascular devices amounted to RMB 608,231 thousand, while orthopedic and other devices generated RMB 3,145 thousand in 2023[15]. - The geographical breakdown of revenue shows that mainland China contributed RMB 549,503 thousand, up from RMB 437,344 thousand in 2022, indicating a growth of about 25.6%[17]. - Revenue from external customers in the cardiac intervention segment reached RMB 625,952,000, a 27.8% increase from RMB 489,704,000 in 2022[21]. - Total segment revenue for 2023 was RMB 801,562,000, up 27.1% from RMB 630,316,000 in 2022[23]. Expenses and Costs - Total operating expenses, including R&D costs, increased to RMB 125,850,000 in 2023 from RMB 99,634,000 in 2022, marking a 26.3% rise[27]. - Sales costs for the reporting period were approximately RMB 314.77 million, an increase of about 24.22% compared to RMB 253.40 million for the year ended December 31, 2022[67]. - Administrative expenses for the reporting period were approximately RMB 99.43 million, an increase of about 54.66% or RMB 35.14 million from approximately RMB 64.29 million for the year ended December 31, 2022[72]. - Research and development expenses for the reporting period were approximately RMB 179.31 million, an increase of about 27.22% or RMB 38.37 million from approximately RMB 140.94 million for the year ended December 31, 2022[73]. Dividends and Shareholder Returns - The board proposed a final dividend of RMB 0.27 per share for the year ended December 31, 2023, compared to RMB 0.24 per share in 2022, reflecting a 12.5% increase[49]. - The company’s cash dividends approved for the previous fiscal year amounted to RMB 40,320 thousand in 2023, down from RMB 43,680 thousand in 2022, a decrease of 7.5%[50]. Investments and Capital Expenditures - The company invested RMB 150 million in non-listed funds managed by Huai Ge Health Management, with RMB 125 million paid as of December 31, 2023[40]. - The company also invested RMB 50 million in another non-listed fund aimed at the healthcare sector, contributing RMB 10 million as of December 31, 2023[40]. - The group reported capital expenditures of approximately RMB 231.20 million for the reporting period, a decrease from RMB 301.06 million in 2022[90]. Research and Development - The company has a strong R&D capability and aims to leverage its comprehensive medical device registration certificates to gain a competitive advantage in the DRG/DIP payment system[51]. - The company plans to further develop its product pipeline and increase R&D investment, focusing on core product development and new product certification in 2024[65]. - The company has a strong R&D team with 334 registered patents and 208 pending patent applications as of December 31, 2023[54]. Corporate Governance and Compliance - The group has adopted a standard code of conduct for securities trading by directors and confirmed compliance during the reporting period[95]. - The Audit Committee, consisting of three members, has confirmed that the financial statements comply with applicable accounting principles and standards[97]. - The company has adhered to all corporate governance codes except for the separation of the roles of Chairman and CEO, which is held by Dr. Liang Dongke[96]. Future Plans and Strategic Initiatives - The company plans to utilize its R&D center to further enhance automation and scale production[65]. - The company is focused on investing in the medical device and biopharmaceutical sectors through various funds[87]. - The company has received approval from shareholders for the 2023 equity incentive plan, which includes the grant of 5,000,000 restricted shares to 17 incentive targets[59].
康德莱医械(01501) - 2023 - 年度业绩